Quarterly report pursuant to Section 13 or 15(d)

INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative)

v3.10.0.1
INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 28, 2016
Jan. 26, 2016
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Intellectual property fees   $ 55,648          
Description for right to purchase perpetual rights  

North America with the option for Central and South America for Naltrexone Implants formulas created by the Seller for 24 months upon receipt of the intellectual property for a fee of $55,648. The Company, within the first 12 months has the right to purchase perpetual rights for above territories for a one-time fee, financed over 5 years. The rights are amortized over the 24 month contract life.

         
Amortization expenses     $ 0 $ 6,936 $ 1,963 $ 13,797  
Therakine, Ltd. [Member]              
License cost $ 2,750,000            
Aggregate purchase price $ 250,000       $ 250,000   $ 250,000
Escrow deposit             $ 75,000
Therakine, Ltd. [Member] | Minimum [Member]              
Milestone payments and royalties 5.00%            
Therakine, Ltd. [Member] | Maximum [Member]              
Milestone payments and royalties 12.00%